×

Immunomic Therapeutics, Inc. Taps Micronaut to Visually Demonstrate Its LAMP-vax Programs

HERSHEY, Pa. and ROCKVILLE, Md., June 16, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces that it has chosen Micronaut, also known as Swiss scientist Martin Oeggerli, to visually demonstrate its LAMP-vax programs through his unique hand-colored Scanning Electronic Microscopy (SEM) photographs.

Micronaut will provide ITI with its unique perspective and license its proprietary molecular images for many of Immunomic's future marketing materials, including, corporate presentations, promotional materials and print advertising.

"Micronaut's work is well respected throughout the scientific community as his work is a direct reflection of actual scientific imagery, rather than just artist rendering, which is often the norm in our industry," said Dr. William Hearl, CEO of ITI. "We are gratified to be working with him and look forward to enhancing our visual presence in the industry through his work."

About Micronaut

Dr. Martin Oeggerli is Micronaut. The Swiss science photographer has appeared in three National Geographic feature articles since December 2009 and has been invited to the 2011 Gwangju Design Biennale by prominent Chinese artist and director Ai Weiwei.

Micronaut is using his scientific expertise and personally-executed preparation, scanning-electron-microscopy (SEM) and post-processing to display his unique perspective with profound clarity.

Since 2005 his award-winning works are published by the greatest names in science and photography, such as the BBC, CELL, Nature, VOGUE, and National Geographic.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a Hershey, PA-based, privately held, clinical stage biotechnology company developing vaccines based on the LAMP technology platform, which was exclusively licensed from Johns Hopkins University. The LAMP-vax vaccine platform aims to increase the immune response to nucleic acid vaccines and simplify vaccine design and delivery for safer, more cost-effective therapies. ITI's LAMP constructs have been validated in human clinical trials for cancer and have been studied in areas including allergy and infectious disease, while internally ITI is focused on developing allergy therapies. Currently, the company is pursuing three main allergy programs:

  • ASP 4070 (Formerly known as JRC-LAMP-vax) - Japanese Red Cedar Vaccine - An innovative potential solution for the over 35 million sufferers of Japanese red cedar pollinosis - Phase I, currently partnered with Astellas Pharma;
    • An analogous vaccine formulation will be developed as a vaccine to treat Mountain Cedar allergy in the US.
  • ARA-LAMP-vax Peanut Allergy Vaccine - A therapeutic vaccine in development, with a goal of mitigating peanut allergy - Beginning Phase I in late 2015/early 2016;
  • Multi Allergen Vaccines (Product Concepts) - Allergy vaccine formulation concepts that would aim to address the major categories of allergies of concern Worldwide - Under study & development.

For more information about ITI and LAMP Technology, please visit www.immunomix.com.

CONTACT: Jules Abraham JQA Partners, Inc. 917-885-7378 jabraham@jqapartners.comSource:Immunomic Therapeutics, Inc.